Genethon gets UK MHRA nod to initiate pivotal phase 3 trial of GNT0004, a low-dose microdystrophin gene therapy for Duchenne muscular dystrophy: Paris, France Wednesday, July 30, ...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed at ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of efficacy- Initial data expected in mid-2026 ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 ...

Procedural flexibility incorporated into many cancer clinical trials during the COVID-19 pandemic had no long-term negative ...

A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need ...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the treatment – called trontinemab – could be the ...